Market Access News | pharmaphorum

News

Business Group on Health statistics graphic

As drug costs for US employers rise, some cut GLP-1s from pl...

Pharmacy now represents 25% of employer healthcare spending, and employers are turning to DTC models and non-traditional PBMs to cut costs.

News

Expanded US Imaavy approval first ever for wAIHA

The FDA has approved Johnson & Johnson's Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune haemolytic anaemia (wAIHA).

News

EC greenlights Acadia’s DAYBU for Rett Syndrome in Europe

Acadia Pharmaceuticals has secured EC approval for DAYBU (trofinetide) for the neurobehavioural symptoms of Rett syndrome in the EU.

News

Japan first approval for GSK’s bepirovirsen for CHB

Japan has approved GSK's antisense oligonucleoide Hibsago (bepirovirsen) as a functional cure in chronic hepatitis B virus infection in adult patients

News

UK MHRA authorises orforglipron private prescription

Eli Lilly has announced that orforglipron (Foundayo) is now available to be prescribed for eligible adults via private prescription.

News

J&J scores EU approval for Tecvayli combo in second line

Johnson & Johnson's multiple myeloma regimen is now approved as a second line treatment in both the US and the EU.

As drug costs for US employers rise, some cut GLP-1s from pl...

Expanded US Imaavy approval first ever for wAIHA

EC greenlights Acadia’s DAYBU for Rett Syndrome in Europe

Japan first approval for GSK’s bepirovirsen for CHB

UK MHRA authorises orforglipron private prescription

J&J scores EU approval for Tecvayli combo in second line

It turns out COPD may be a laughing matter after all

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks